Background: Para-18F-fluorohippuric acid (18F-PFH) and ortho-124I-iodohippuric acid (124IOIH)
were recently identified as potential radiotracers suitable for conducting renography using positron
emission tomography (PET). The aim of this work was to estimate preliminary human-equivalent internal
radiation dose of 18F-PFH and 124I-OIH using the biodistribution data reported in healthy rats. The
results were compared with the absorbed dose data of technetium-99m-mercaptoacetyltriglycine (99mTc-
MAG3) as documented in the International Commission on Radiological Protection (ICRP) publication
Methods: The medical internal radiation dose (MIRD) formula was applied to extrapolate data from rats
to human and to project the absorbed radiation dose for various organs in humans. S factor was calculated
by Monte-Carlo N-particle (MCNP) simulation.
Results: Our dose prediction shows that an injection of 18F-PFH or 124I-OIH in humans would result in
an estimated effective absorbed dose of 0.09 or 0.17 µSv/MBq respectively for whole body, which is
about 135 or 73 times respectively lower than that obtained with an injection of 99mTc-MAG3. All organs
except kidneys would receive an estimated effective absorbed dose of <0.1 µSv/MBq for 18F-PFH
or 124I-OIH. Kidneys would receive a dose of 0.83 or 0.77 µSv/MBq respectively for 18F-PFH or 124I-OIH.
Conclusions: Our results indicate that 18F-PFH and 124I-OIH would deliver much safer levels and lower
radiation doses to the patients compared to 99mTc-MAG3 and warrants a clinical trial to estimate the
radiation doses more accurately.
Keywords: 18F-PFH, 124I-OIH, PET, para-18F-fluorohippurate, ortho-124I-iodohippurate, renal agent, tubular secretion, renography,
Rights & PermissionsPrintExport